Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AVE1625 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| AVE1625 | DRUG | - |
Inclusion Criteria: * The diagnosis of Alzheimer's disease * Recent brain image(Computerized Axial Tomographic Scan -CAT scan or Magnetic Resonance Imaging - MRI) * Mild to moderate range of disease; not too severe Exclusion Criteria: * Severe or unstable medical diseases * Neurological disorder ...
Top 20 of 24 competitors
AVE1625 is an investigational small molecule being studied for the treatment of Alzheimer Disease. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities. The drug is being evaluated for its activity in patients with mild to moderate Alzheimer's disease.
AVE1625 is being developed by Sanofi, a multinational pharmaceutical company listed on the stock exchange under the ticker symbol SNY. Sanofi is conducting clinical trials to evaluate the safety and efficacy of this investigational drug for Alzheimer Disease.
AVE1625 is in Phase 1 clinical development. It is an investigational drug, meaning it is not yet approved for commercial use. The Phase 1 trial has been completed, and the drug is still in the early stages of clinical testing for Alzheimer Disease.
AVE1625 has one completed clinical trial registered under the identifier NCT00380302. This Phase 1 study, titled 'Activity of AVE1625 in Mild to Moderate Alzheimer's Patients,' enrolled 162 participants across the United States, France, Italy, Netherlands, and Sweden. The trial was randomized and double-blind.
AVE1625 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for Alzheimer Disease. The drug has completed a Phase 1 trial, but it has not yet received regulatory approval for any use.